CSIC researchers will use a type of coronavirus parasites’ to fight it

A team of researchers from the Higher Council for Scientific Research (CSIC) is leading a project to develop antiviral drugs to prevent the replication of the SARS-Cov-2 coronavirus, which caused the Covid-19 pandemic. The study focuses on so-called Dips (Interfering Defective Particles), a common type of molecular parasites specific to RNA viruses, without infective capacity on their own but taking advantage of their machinery to replicate and thus interfere in infection.

The project, which brings together researchers from the Institute of Integrative Biology of Systems of the CSIC (I²Sysbio, a joint project of the CSIC and the University of Valencia), forms part of the Global Health Platform, with more than 200 research groups working together to address the challenges posed by the coronavirus epidemic.

CSIC Webinar: Summer has come, Is the pandemic over?

In this webinar several researchers from the CSIC and other institutions, will address, from different points of view, those aspects related to the arrival of the summer in the middle of the Covid-19 pandemic. Date: 24th of June at 20:10.

Trial of Oxford COVID-19 vaccine in South Africa begins

Participants in South Africa’s first clinical trial for a vaccine against COVID-19 are to be vaccinated this week.

The first clinical trial in South Africa and on the continent for a COVID-19 vaccine was announced today, 23 June, at a virtual press conference hosted by the University of the Witwatersrand, Johannesburg (Wits).

Wits University is collaborating with the University of Oxford and the Oxford Vaccine Group on the South African trial. The South African Ox1Cov-19 Vaccine VIDA-Trial aims to find a vaccine that will prevent infection by SARS-CoV-2, the virus that causes COVID-19. The technical name of the vaccine is ChAdOx1 nCoV-19,as it is made from a virus called ChAdOx1, which is a weakened and non-replicating version of a common cold virus (adenovirus). The vaccine has been engineered to express the SARS-CoV-2 spike protein.

The vaccine was developed at the University of Oxford’s Oxford Jenner Institute and is currently on trial in the UK, where over 4,000 participants are already enrolled into the clinical trial and enrolment of an additional 10, 000 participants is planned.


The University of Cambridge’s Festival of Wellbeing is an annual programme of talks and activities with the aim of promoting good mental and physical health for all.  

This year the University has organised a one-week programme of virtual events and activities for you to participate in. Talks and workshops require you to book in advance, but all other content is pre-recorded and can be accessed from the start of the Festival, June 22nd. 

Find out all the info here.